



**SUPRIYA LIFESCIENCE LIMITED**  
CIN No: L51900MH2008PLC180452  
207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: L51900MH2008PLC180452  
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

(₹ In million)

**Part I -Statement of Standalone Unaudited Financial Results for the Quarter and Nine month ended 31st December, 2025**

Sr.No.	Particulars	Quarter ended 31-12-2025	Quarter ended 30-09-2025	Quarter ended 31-12-2024	Nine month ended 31-12-2025	Nine month ended 31-12-2024	Year ended 31-03-2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	<b>Income</b>						
I	Revenue from Operations	2,064.40	1,998.33	1,856.48	5,513.47	5,123.76	6,964.85
II	Other Income	26.11	27.25	20.98	80.10	68.40	98.15
III	<b>Total Income</b>	<b>2,090.51</b>	<b>2,025.58</b>	<b>1,877.45</b>	<b>5,593.57</b>	<b>5,192.16</b>	<b>7,063.00</b>
2	<b>Expenses</b>						
	a) Cost of Materials Consumed	772.98	606.83	135.97	1,817.57	1,309.05	2,324.36
	b) Purchase of Stock in Trade	-	-	-	-	-	-
	c) Change in inventories of finished goods, work in progress & stock in trade.	(160.98)	(49.53)	481.82	(330.55)	254.46	(212.59)
	d. Employee benefit expenses	246.94	244.81	197.72	718.63	595.42	805.19
	e. Finance Cost	4.94	4.15	5.07	14.21	12.68	16.86
	f. Depreciation & amortisation expense	68.21	66.39	49.64	199.11	143.63	204.44
	g. Other expenditure	484.64	469.75	381.44	1,343.52	1,032.72	1,439.93
IV	<b>Total Expenses</b>	<b>1,416.73</b>	<b>1,342.40</b>	<b>1,251.65</b>	<b>3,762.49</b>	<b>3,347.96</b>	<b>4,578.19</b>
V	<b>Profit/(loss) before Exceptional Items &amp; Tax (III-IV)</b>	<b>673.78</b>	<b>683.18</b>	<b>625.80</b>	<b>1,831.08</b>	<b>1,844.20</b>	<b>2,484.80</b>
VI	Exceptional Items	(4.58)	-	-	(4.58)	-	-
VII	<b>Profit/(loss) before Tax (V-VI)</b>	<b>669.20</b>	<b>683.18</b>	<b>625.80</b>	<b>1,826.50</b>	<b>1,844.20</b>	<b>2,484.80</b>
VIII	<b>Tax Expense</b>						
	a) Current Tax	153.24	151.58	137.72	410.17	438.85	566.57
	b) Deferred Tax	19.21	27.33	20.25	67.41	29.58	38.66
IX	<b>Profit/(Loss) for the period from Continuing Operations (VII-VIII)</b>	<b>496.75</b>	<b>504.27</b>	<b>467.83</b>	<b>1,348.92</b>	<b>1,375.76</b>	<b>1,879.58</b>
X	Profit/(Loss) from discontinued operations before tax	-	-	-	-	-	-
XI	Tax Expense of discontinued operations	-	-	-	-	-	-
XII	<b>Profit/(Loss) from discontinued operations after tax (X-XI)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII	<b>Profit/(Loss) for the period (IX+XII)</b>	<b>496.75</b>	<b>504.27</b>	<b>467.83</b>	<b>1,348.92</b>	<b>1,375.76</b>	<b>1,879.58</b>
XIV	<b>Other Comprehensive Income</b>						
	A (i) Items that will not be reclassified to profit or loss	0.54	0.45	0.81	(1.88)	(2.83)	(1.67)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	(0.14)	(0.11)	(0.20)	0.47	0.71	0.42
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	<b>Total Comprehensive Income for the period (XIII+XIV)</b>	<b>497.15</b>	<b>504.61</b>	<b>468.43</b>	<b>1,347.51</b>	<b>1,373.65</b>	<b>1,878.33</b>
XVI	<b>Earnings per equity Share (for continuing operation):</b>						
	(1) Basic (In ₹)	6.17	6.27	5.82	16.76	17.07	23.35
	(2) Diluted (In ₹)	6.17	6.27	5.82	16.76	17.07	23.35
XVII	<b>Earnings per equity Share (for discontinued operation):</b>						
	(1) Basic (In ₹)	-	-	-	-	-	-
	(2) Diluted (In ₹)	-	-	-	-	-	-
XVIII	<b>Earnings per equity Share (for discontinued &amp; continuing operations):</b>						
	(1) Basic (In ₹)	6.17	6.27	5.82	16.76	17.07	23.35
	(2) Diluted (In ₹)	6.17	6.27	5.82	16.76	17.07	23.35



See accompanying notes to the financial statements:

**Notes:-**

1. The unaudited standalone financial results of the Company for the quarter and nine month ended December 31, 2025 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as amended.
2. The above unaudited standalone financial results of the Company for the quarter and nine month ended December 31, 2025 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their respective meetings held on February 09, 2026.
3. The Company has adopted Ind AS 116 "Leases" effective April 01, 2019, using modified retrospective method. The Company has applied the standard to all its leases with the cumulative impact recognized on the date of initial application i.e. April 01, 2019.
4. The company does not have any subsidiary/associate/joint venture company as on December 31, 2025.
5. Effective November 21, 2025, the Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). The company has identified impact of New Labour Codes amounting to Rs. 4.58 Million and presented such amount under exceptional item. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact of these will be accounted in accordance with applicable accounting standards as and when these developments are known and applicable.
6. The figures of the previous periods have been regrouped wherever necessary to confirm to the current period presentation.

For Supriya Lifescience Limited

  
Dr. Satish Waman Wagh  
Chairman and Executive Director.  
DIN: 01456982

Place :- Mumbai  
Date :- February 09, 2026

